Stockscreener 앱 받기
0.3025
1.17%
0.0035
전일 마감가:
$0.299
열려 있는:
$0.3036
하루 거래량:
217.29K
Relative Volume:
0.94
시가총액:
$24.64M
수익:
$1.22M
순이익/손실:
$-14.15M
주가수익비율:
-1.1635
EPS:
-0.26
순현금흐름:
$-6.55M
1주 성능:
+0.83%
1개월 성능:
-6.35%
6개월 성능:
-20.18%
1년 성능:
-24.86%
1일 변동 폭
$0.3022
$0.3097
1주일 범위
$0.2953
$0.315
52주 변동 폭
$0.2525
$0.55
IGC Pharma Inc Stock (IGC) Company Profile
명칭
IGC Pharma Inc
전화
301-983-0998
주소
4336 Montgomery Avenue, Bethesda, MD
IGC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.3025 | 24.64M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
IGC Pharma Inc 주식(IGC)의 최신 뉴스
IGC Pharma Highlights Alzheimer’s Research Progress - TipRanks
BARDA’s $375M to Shionogi for COVID-19 tops early list of 2025 grants - BioWorld MedTech
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - sharewise
IGC Pharma Launches Clinical Trial Site in Puerto Rico | IGC Sto - GuruFocus
IGC Pharma Launches Clinical Trial Site in Puerto Rico | IGC Stock News - GuruFocus
IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market | IGC Stock News - GuruFocus
IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market - ACCESS Newswire
IGC Pharma Targets Puerto Rico's 12.5% Alzheimer's Rate in Strategic Trial Expansion - Stock Titan
IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Oppor - GuruFocus
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC - GuruFocus
IGCPharma (IGC) Confirms Genetic Safety of Alzheimer's Drug Ingr - GuruFocus
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting - ACCESS Newswire
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline - Seeking Alpha
Press Release Distribution & PR Platform - ACCESS Newswire
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results" - ACCESS Newswire
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy - ACCESS Newswire
Is IGC Pharma Inc (IGC) a good investment opportunity? - uspostnews.com
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 - ACCESS Newswire
IGC Pharma Welcomes Strategic Investment from Advisors - PharmiWeb.com
IGC Pharma (IGC) Secures $475K Investment to Advance Alzheimer's Trial | IGC Stock News - GuruFocus
IGC Pharma Welcomes Strategic Investment from Advisors | IGC Sto - GuruFocus
IGC Pharma Welcomes Strategic Investment From Advisors - Barchart.com
The 7 Best Stocks Under 50 Cents To Buy For June 2025! - The Stock Dork
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporti - GuruFocus
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs | IGC Stock News - GuruFocus
Former MassBio CEO Joins IGC Pharma's Advisory Board to Advance AI-Powered Alzheimer's Programs - Stock Titan
India Globalization Capital : IGC Announces Results of its 2020 Annual Stockholders Meeting - marketscreener.com
IGC Pharma, Inc. (IGC) Reports Q3 Loss, Tops Revenue Estimates - MSN
IGC Pharma expands CALMA trial with addition of Butler Hospital Program - Yahoo Finance
IGC Pharma Expands Phase 2 Alzheimer's Trial Site - marketscreener.com
IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program - Newswire.com
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health - BioSpace
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addi - GuruFocus
IGC Pharma announces CALMA Phase 2 trial expansion with Miami Jewish Health - TipRanks
IGC Pharma expands CALMA clinical trial - TipRanks
IGC Pharma Accelerates Alzheimer's Breakthrough: Key Research Center Joins Phase 2 Trial - Stock Titan
IGC Pharma posts promising interim data for Alzheimer’s therapy - MSN
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances - BioSpace
Breakthrough: New Alzheimer's Drug Cuts Sleep Disturbances by 78% in Phase 2 Trial - Stock Titan
IGC adds new clinical site in Canada for Alzheimer’s agitation therapy trial - Clinical Trials Arena
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences - BioSpace
IGC Pharma Adds Canadian Site to Phase 2 Trial of Investigational Alzheimer's Dementia Therapy - MarketScreener
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida - ACCESS Newswire
IGC Pharma Inc (IGC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.86%
1.98%
자본화:
|
볼륨(24시간):